{
    "medicine_id": "36dbd9686d927af2159603d78585c95f462a910d",
    "platform_id": "DB04468",
    "metadata": {
        "name": "Lac tol Pwr 50gm pck 204 mg Tablet",
        "composition": "204 mg Afimoxifene",
        "clinical_particulars": {
            "therapeutic_indications": "For the potential treatment of menstrual cycle related mastalgia fibrocystic breast disease breast disease gynecomastia and Keloid scarring",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "NA",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Afimoxifene"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Afimoxifene"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Afimoxifene"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Afimoxifene"
                    },
                    {
                        "drugbank-id": "DB04938",
                        "description": "The risk or severity of adverse effects can be increased when Afimoxifene is combined with Ospemifene"
                    },
                    {
                        "drugbank-id": "DB15690",
                        "description": "Afimoxifene may decrease effectiveness of Fluoroestradiol F 18 as a diagnostic agent"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}